Format

Send to

Choose Destination
Oncotarget. 2016 May 31;7(22):31907-25. doi: 10.18632/oncotarget.8201.

Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.

Author information

1
Research and Development Unit, Celther Polska Ltd., Lodz, Poland.
2
Department of Tumor Biology, Medical University of Lodz, Lodz, Poland.
3
Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland.

Abstract

Glioblastoma is the most common and malignant brain tumor, characterized by high cellular heterogeneity. About 50% of glioblastomas are positive for EGFR amplification, half of which express accompanying EGFR mutation, encoding truncated and constitutively active receptor termed EGFRvIII. Currently, no cell models suitable for development of EGFRvIII-targeting drugs exist, while the available ones lack the intratumoral heterogeneity or extrachromosomal nature of EGFRvIII.The reports regarding the biology of EGFRvIII expressed in the stable cell lines are often contradictory in observations and conclusions. In the present study, we use DK-MG cell line carrying endogenous non-modified EGFRvIII amplicons and derive a sub-line that is near depleted of amplicons, whilst remaining identical on the chromosomal level. By direct comparison of the two lines, we demonstrate positive effects of EGFRvIII on cell invasiveness and populational growth as a result of elevated cell survival but not proliferation rate. Investigation of the PI3K/Akt indicated no differences between the lines, whilst NFκB pathway was over-active in the line strongly expressing EGFRvIII, finding further supported by the effects of NFκB pathway specific inhibitors. Taken together, these results confirm the important role of EGFRvIII in intrinsic and extrinsic regulation of tumor behavior. Moreover, the proposed models are stable, making them suitable for research purposes as well as drug development process utilizing high throughput approach.

KEYWORDS:

DK-MG; EGFR; EGFRvIII; glioblastoma

PMID:
27004406
PMCID:
PMC5077985
DOI:
10.18632/oncotarget.8201
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center